Effects of chronic cytochrome P-450 inhibition on the course of hypertension and end-organ damage in Ren-2 transgenic rats

Vascular Pharmacology

Volumn 47, Issue 2-3, 2007, Pages 145-159

  Chábová, Vera Certikova ^a,b   Kramer, Herbert J ^c   Vaněčková, Ivana ^b,d   Vernerová, Zdena ^a,b   Eis, Václav ^a,b   Tesař, Vladimír ^a   Škaroupková, Petra ^b   Thumová, Monika ^b   Schejbalová, Stanislava ^b   Husková, Zuzana ^b,d   Vaňourková, Zdenka ^b,d   Kolský, Alexander ^e   Imig, John D ^f   Červenka, Luděk ^a,b,f  

^a CHARLES UNIVERSITY   (Czech Republic)

^b INSTITUTE FOR CLINICAL AND EXPERIMENTAL MEDICINE   (Czech Republic)

^c Medical Policlinic   (Germany)

^d Center for Cardiovascular Research   (Czech Republic)

^e FAKULTNÍ THOMAYEROVA NEMOCNICE   (Czech Republic)

^f MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

Cytochrome P 450; Hypertension; Renin transgenic rats; Renin angiotensin system

Indexed keywords

1 AMINOBENZOTRIAZOLE; 20 HYDROXYICOSATETRAENOIC ACID; ALKANE 1 MONOOXYGENASE; ANGIOTENSIN II; CYTOCHROME P450; ENZYME; EPOXYGENASE; EPOXYICOSATRIENOIC ACID; PHOSGENE; PROTEIN; SODIUM CHLORIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERY CONSTRICTION; ARTICLE; BLOOD PRESSURE REGULATION; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME INHIBITION; GLOMERULOSCLEROSIS; HEART HYPERTROPHY; HYPERTENSION; KIDNEY CORTEX; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN URINE LEVEL; RAT; RAT STRAIN; RENAL ARTERY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RENOVASCULAR HYPERTENSION; SPRAGUE DAWLEY RAT; TRANSGENE;

ALKANE 1-MONOOXYGENASE; ANIMALS; BLOOD PRESSURE; CARDIOMEGALY; COBALT; CYTOCHROME P-450 ENZYME SYSTEM; DISEASE MODELS, ANIMAL; ENZYME INHIBITORS; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; HETEROZYGOTE; HYDROXYEICOSATETRAENOIC ACIDS; HYPERTENSION; KIDNEY CORTEX; MALE; OXYGENASES; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; RENIN; RENIN-ANGIOTENSIN SYSTEM; TRIAZOLES; VASOCONSTRICTION;

EID: 34547100988     PISSN: 15371891     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vph.2007.05.005     Document Type: Article

References (68)

1. Abraham N.G., and Kappas A. Heme oxygenase and the cardiovascular-renal system. Free Radic. Biol. Med. 39 (2005) 1-25
2. Alonso-Galicia M., Maier K.G., Greene A.S., Cowley A.W., and Roman R.J. Role of 20-hydroxyeicosatetraenoic acid in the renal and vasoconstrictor actions of angiotensin II. Am. J. Physiol. 283 (2002) R60-R68
3. Arendshorst W.J., and Beierwaltes W.H. Renal and nephron hemodynamics in spontaneously hypertensive rats. Am. J. Physiol. 236 (1979) F246-F251
4. Campbell W.B., Gebremedhin D., Pratt P.F., and Harder D.R. Identification of epoxyeicosatrienoic acids as endothelium-derived hyperpolarizing factors. Circ. Res. 78 (1996) 415-423
5. Carroll M.A., Schwartzman M., Baba M., Miller M.J.S., and McGiff J.C. Renal cytochrome P-450-related arachidonate metabolism in rabbit aortic coarctation. Am. J. Physiol. 255 (1988) F151-F157
6. Carroll M.A., Kemp R., Cheng M.K., and McGiff J.C. Regulation of preglomerular microvascular 20-hydroxyeicosatetraenoic acid levels by salt depletion. Med. Sci. Monit. 7 (2001) 567-572
7. Croft K.D., McGiff J.C., Sanchez-Mendoza A., and Carroll M.A. Angiotensin II release 20-HETE from rat renal microvessels. Am. J. Physiol. 279 (2000) F544-F551
8. Da Silva J.L., Tiefenthaler M., Park E., Escalante B., Schwartzman M.L., Levere R.D., and Abraham N.G. Tin-mediated heme oxygenase gene activation and cytochrome P450 arachidonate hydroxylase inhibition in spontaneously hypertensive rats. Am. J. Med. Sci. 307 (1994) 173-181
9. Dos Santos E.A., Dahly-Vernon A.J., Hoagland K.M., and Roman R.J. Inhibition of the formation of EETs and 20-HETE with 1-aminobenzotriazole attenuates pressure natriuresis. Am. J. Physiol. 287 (2004) R58-R68
10. Escalante B., Sacerdoti D., Davidian M.M., Lanaiado-Schwartzman M., and McGiff J.C. Chronic treatment with tin normalizes blood pressure in spontaneously hypertensive rats. Hypertension 17 (1991) 776-779
11. 2+ current. J. Physiol. 507 (1998) 771-781
12. Hall J.E., and Brands M.W. The renin-angiotensin-aldosterone system: renal mechanisms and circulatory homeostasis. In: Seldin D.W., and Giebisch G. (Eds). The Kidney: Physiology and Pathophysiology (2000), Lippincott Williams and Wilkins, Philadelphia 1009-1046
13. Hartner A., Porst M., Klanke B., Cordasic N., Veelken R., and Hilgers K.F. Angiotensin II formation in the kidney and nephrosclerosis in Ren-2 hypertensive rats. Nephrol. Dial. Transplant. 21 (2006) 1778-1785
14. Heller J., and Hellerova S. Long-term effect on blood pressure of early brief treatment by different antihypertensive agents: a study in the Prague hypertensive rat. Kidney Blood Press Res. 21 (1998) 445-451
15. Hoagland K.M., Flasch A.K., and Roman R.J. Inhibitors of 20-HETE formation promote salt-sensitive hypertension in rats. Hypertension 42 (2003) 669-673
16. + channels in vascular smooth muscles by cytochrome P450 metabolites of arachidonic acid. Eur. J. Pharmacol. 230 (1993) 215-221
17. Husková Z., Kramer H.J., Vaňourková Z., and Červenka L. Effects of changes in sodium balance on plasma and kidney angiotensin II levels in anesthetized and conscious Ren-2 transgenic rats. J. Hypertens. 24 (2006) 517-527
18. Husková Z., Kramer H.J., Thumová M., Vaňurková Z., Bürgelová M., Teplan V., Malý J., and Červenka L. Effects of anesthesia on plasma and kidney ANG II levels in normotensive and ANG II-dependent hypertensive rats. Kidney Blood Press Res. 29 (2006) 74-83
19. Imig J.D. Afferent arteriolar reactivity to angiotensin II is enhanced during the early phase of angiotensin II hypertension. Am. J. Hypertens. 13 (2000) 810-818
20. Imig J.D. Epoxide hydrolase and epoxygenase metabolites as therapeutic targets for renal diseases. Am. J. Physiol. 289 (2005) F496-F503
21. 2 and modulation by lipoxygenase and P-450 pathways. Am. J. Physiol. 273 (1997) F274-F282
22. Imig J.D., Zou A.P., Ortiz de Montellano P.R., Sui Z., and Roman R.J. Cytochrome P-450 inhibitors alter afferent arteriolar responses to elevations in pressure. Am. J. Physiol. 266 (1996) H1879-H1885
23. Imig J.D., Navar L.G., Roman R.J., Reddy K.K., and Falck J.R. Actions of epoxygenase metabolites on the preglomerular vasculature. J. Am. Soc. Nephrol. 7 (1996) 2364-2370
24. Imig J.D., Falck J.R., and Inscho E.W. Contribution of cytochrome P450 epoxygenase and hydroxylase pathways to afferent arteriolar autoregulatory responsiveness. Br. J. Pharmacol. 127 (1999) 1399-1405
25. Imig J.D., Pham B.T., LeBlanc E.A., Reddy K.M., Falck J.R., and Inscho E.W. Cytochrome P450 and cyclooxygenase metabolites contribute to the endothelin-1 afferent arteriolar vasoconstrictor and calcium responses. Hypertension 35 (2000) 307-312
26. Imig J.D., Zhao X., Falck J.R., Wei S., and Capdevila J.H. Enhanced renal microvascular reactivity to angiotensin II in hypertension is ameliorated by the sulfonimide analog of 11,12-epoxyeicosatrienoic acid. J. Hypertens. 19 (2001) 983-992
27. Imig J.D., Falck J.R., Wei S., and Capdevila J.H. Epoxygenase metabolites contribute to nitric oxide-independent afferent arteriolar vasodilatation in response to bradykinin. J. Vasc. Res. 38 (2001) 247-255
28. Imig J.D., Zhao X., Capdevila J.H., Morisseau C., and Hammock B.D. Soluble epoxide hydrolase inhibition lowers arterial blood pressure in angiotensin II hypertension. Hypertension 39 (2002) 690-694
29. Imig J.D., Zhao X., Zaharis C.Z., Olearczyk J.J., Pollock D.M., Newman J.W., Kim H.I., Watanabe T., and Hammock B.D. An orally active epoxide hydrolase inhibitor lowers blood pressure and provides renal protection in salt-sensitive hypertension. Hypertension 46 (2005) 975-981
30. Jacinto S.M., Mullins J.J., and Mitchell K.D. Enhanced renal vascular responsiveness to angiotensin II in hypertensive ren-2 transgenic rats. Am. J. Physiol. 276 (1999) F315-F322
31. Joly E., Seqqat R., Flamion B., Caron N., Michal A., Imig J.D., and Kramp R. Increased renal vascular reactivity to angiotensin II after unilateral nephrectomy in the rat involves 20-HETE. Am. J. Physiol. 291 (2006) R977-R986
32. Kaergel E., Muller D.N., Honeck H., Theuer J., Shagdarsuren E., Mullally A., Luft F.C., and Schunck W.H. P450-dependent arachidonic acid metabolism and angiotensin II-induced renal damage. Hypertension 40 (2002) 273-279
33. Kaide J., Wang M.H., Wang J.S., Zhang F., Gopal V.R., Falck J.R., Nasjletti A., and Laniado-Schwartzman M. Transfection of CYP4A1 cDNA increases vascular reactivity in renal interlobar arteries. Am. J. Physiol. 284 (2003) F51-F56
34. Kobori H., Nishiyama A., Abe Y., and Navar L.G. Urinary angiotensinogen as an indicator of intrarenal status in hypertension. Hypertension 41 (2003) 42-49
35. Kohagure K., Endo Y., Ito O., Arima S., Omata K., and Ito S. Endogenous nitric oxide and epoxyeicosatrienoic acids modulate angiotensin II-induced constriction in the rabbit afferent arteriole. Acta Physiol. Scand. 168 (2000) 107-112
36. 1 receptor blockade in hypertensive Ren-2 transgenic rats. J. Hypertens. 22 (2004) 819-825
37. Kopkan L., Kramer H.J., Huskova Z., Vaňourková Z., Škaroupková P., Thumová M., and Červenka L. The role of intrarenal angiotensin II in the development of hypertension in Ren-2 transgenic rats. J. Hypertens. 23 (2005) 1531-1539
38. Kroetz D.L., and Xu F. Regulation and inhibition of arachidonic acid ω-hydroxylases and 20-HETE formation. Annu. Rev. Pharmacol. Toxicol. 45 (2005) 413-438
39. Li P.L., and Campbell W.B. Regulation of potassium channels in coronary smooth muscle through a guanine nucleotide binding protein. Circ. Res. 80 (1997) 877-884
40. Madhun Z.T., Goldthwait D.A., McKay D., Hopfer U., and Douglas J.G. An epoxygenase metabolite of arachidonic acid mediates angiotensin II-induced rises in cytosolic calcium in rabbit proximal tubule epithelial cells. J. Clin. Invest. 88 (1991) 456-461
41. Maier K.G., Henderson L., Narayanan J., Alonso-Galicia M., Falck J.R., and Roman R.J. Fluorescent HPLC assay for 20-HETE and other P-450 metabolites of arachidonic acid. Am. J. Physiol. 279 (2000) H863-H871
42. Meschter C.I., Mico B.A., Mortillo M., Feldman D., Garland W.A., Riley J.A., and Kaufman L.S. A 13-week toxicologic and pathologic evaluation of prolonged cytochromes P-450 inhibition by 1-aminobenzotriazole in male rats. Fundam. Appl. Toxicol. 22 (1994) 369-381
43. Mullins JJ., Peters J., and Ganten D. Fulminant hypertension in transgenic rats harboring the mouse Ren-2 gene. Nature 344 (1990) 541-544
44. Muthalif M.M., Karzoun N.A., Gaber L., Khandekar Z., Benter I.F., Saeed A.F., Parmentier J.H., Estes A., and Malik K.U. Angiotensin II-induced hypertension: contribution of Ras GTPase/mitogen-activated protein kinase and cytochrome P-450 metabolites. Hypertension 36 (2000) 604-609
45. Navar L.G. The intrarenal renin-angiotensin system in hypertension. Kidney Int. 65 (2004) 1522-1532
46. Opočenský I., Kramer H.J., Bäcker A., Vernerová Z., Eis V., Červenka L., and Vaněčková I. Late-onset endothelin-A receptor blockade substantially improves survival rate in homozygous hypertensive Ren-2 rats. Hypertension 48 (2006) 965-971
47. Oyekan A.O., and McGiff J.C. Cytochrome p-450-derived eicosanoids participates in the renal functional effects of ET-1 in the anaesthetized rat. Am. J. Physiol. 274 (1998) R52-R61
48. Oyekan A.O., McAward K., Conetta J., Rosenfeld L., and McGiff J.C. Endothelin-1 and CYP450 arachidonate metabolites interact to promote tissue injury in DOCA-salt hypertension. Am. J. Physiol. 276 (1999) R766-R775
49. Quigley R., Baum M., Reddy K.M., Griener J.C., and Falck J.R. Effects of 20-HETE and 19(S)-HETE on rabbit proximal straight tubule volume transport. Am. J. Physiol. 278 (2000) F949-F953
50. Randriamboavonjy V., Busse R., and Fleming I. 20-HETE-induced contraction of small coronary arteries depends on the activation of Rho-kinase. Hypertension 41 (2003) 801-806
51. Randriamboavonjy V., Kiss L., Falck J.R., Busse R., and Fleming I. The synthesis of 20-HETE in small porcine coronary arteries antagonizes EDHF-mediated relaxation. Cardiovasc. Res. 65 (2005) 487-494
52. Roman R.J. P-450 metabolites of arachidonic acid in the control of cardiovascular function. Physiol. Rev. 82 (2002) 131-185
53. Sacerdoti D., Esclanate B., Abraham N.G., McGiff J.C., Levere R.D., and Schwartzman M.L. Treatment with tin prevents the development of hypertension in spontaneously hypertensive rats. Science 243 (1989) 388-390
54. Sakairi Y., Jacobson H.R., Noland D.T., Capdevila J.H., Falck J.R., and Breyer M.D. 5,6-EET inhibits ion transport in collecting duct by stimulating endogenous prostaglandin synthesis. Am. J. Physiol. 268 (1995) F931-F939
55. Sandberg M.C., and Laborde C. Glomerulosclerosis and tubulointerstitial fibrosis are attenuated with 17-beta-estradiol in the aging Dahl salt sensitive rat. J. Am. Soc. Nephrol. 15 (2004) 1546-1556
56. Sarkis A., Lopez B., and Roman R.J. Role of 20-hydroxyeicosatetraenoic acid and epoxyeicosatrienoic acids in hypertension. Curr. Opin. Nephrol. Hypertens. 13 (2004) 205-214
57. Su P., Kaushal K.M., and Kroetz D.L. Inhibition of renal arachidonic acid ω-hydroxylase activity with ABT reduces blood pressure in the SHR. Am. J. Physiol. 275 (1998) R426-R438
58. Vaněčková I., Kramer H.J., Bäcker A., Vernerová Z., Opočenský M., and Červenka L. Early endothelin-A receptor blockade decreases blood pressure and ameliorates end-organ damage in homozygous Ren-2 rats. Hypertension 46 (2005) 969-974
59. Vaněčková I., Škaroupková P., Dvořák P., Čertíková Chábová V., Tesař V., Bader M., Ganten D., and Kramer H.J. Effects of sodium restriction and cyclooxygenase-2 inhibition on the course of hypertension, proteinuria and cardiac hypertrophy in Ren-2 transgenic rats. Physiol. Res. 54 (2005) 17-24
60. Vaněčková I., Kramer H.J., Bäcker A., Schejbalová S., Vernerová Z., Eis V., Opočenský M., Dvořák P., and Červenka L. Early-onset endothelin receptor blockade in hypertensive heterozygous Ren-2 rats. Vasc. Pharmacol. 45 (2006) 163-170
61. + channel in the thick ascending limb of the rat kidney. J. Gen. Physiol. 106 (1995) 727-743
62. Wang D., Borrego-Conde L.J., Falck J.R., Sharma K.K., Wilcox C.S., and Umans J.G. Contribution of nitric oxide, EDHF, and EETs to endothelium-dependent relaxation in renal afferent arterioles. Kidney Int. 63 (2003) 2187-2193
63. +-ATPase activity in the thick ascending loop of Henle. Am. J. Physiol. 292 6 (2007) R2400-R2005
64. Zhao X., and Imig J.D. Kidney CYP450 enzymes: biological actions beyond drug metabolism. Curr. Drug Metab. 4 (2003) 73-84
65. Zhao X., Yamamoto T., Newman J.W., Kim I.H., Watanabe T., Hammock B.D., Stewart J., Pollock J.S., Pollock D.M., and Imig J.D. Soluble epoxide hydrolase inhibition protects the kidney from hypertension-induced damage. J. Am. Soc. Nephrol. 15 (2004) 1244-1253
66. Zicha J., and Kuneš J. Ontogenetic aspects of hypertension development: analysis in the rat. Physiol. Rev. 79 (1999) 1227-1282
67. + channel in renal arterioles. Am. J. Physiol. 270 (1996) R228-R237
68. + channel activity. Am. J. Physiol. 270 (1996) F822-F832